 Bristol-Myers Squibb Co NYSE: BMY and Agenus Inc NASDAQ: AGEN have entered into a global exclusive license agreement, under which Bristol Myers will receive an exclusive license to Agenus AGEN1777 and a second undisclosed target. Bristol Myers Squibb will become solely responsible for the development and subsequent commercialization of AGEN1777 and its related products worldwide. 